source
- Tango Therapeutics reports 82% tumor response in combo trial for advanced pancreatic cancerTango Therapeutics and Revolution Medicines presented data showing that their experimental combination therapy produced tumor responses in 82% of patients with a specific form of advanced pancreati…
- Tango’s pancreatic cancer combo shows striking promise at ESMO, building on Revolution Medicines’ earlier successTango presented new data on its pancreatic cancer combination at the opening of the ESMO conference, highlighting a striking level of activity that builds on earlier success reported by Revolution…STAT · 17d agoPositive readoutPositive